Cantor Fitzgerald initiated coverage on LifeMD with a new price target
$LFMD
Medical/Nursing Services
Health Care
Cantor Fitzgerald initiated coverage of LifeMD with a rating of Overweight and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/23/2024 | $11.00 | Buy | B. Riley Securities |
| 6/5/2024 | $12.00 | Overweight | KeyBanc Capital Markets |
| 11/30/2023 | $10.00 | Buy | Craig Hallum |
| 7/21/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/3/2023 | $9.00 | Buy | H.C. Wainwright |
| 3/10/2022 | $14.00 | Buy | Colliers Securities |
| 10/4/2021 | $16.00 | Buy | B. Riley Securities |
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of November: Craig-Hallum 15th Annual Alpha Select Conference, November 19 at the Sheraton NY Times Square Hotel. Management will hold one-on-one meetings with investors. Stephens NASH24 Conference, November 20 at the Grand Hyatt Nashville. Management will hold one-on-one meetings with investors.BTIG Digital Health Forum, November 25. Management will participate in a virtual panel discussion titled "Primary Care is the Solution" at 10:00 a.m. Eastern time a
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-717-1738International Dial-In:646-307-1865Conference ID:73461Live & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmac
Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the price target from $12 to $10.
LifeMD, Inc. (NASDAQ:LFMD) today announced the launch of private health insurance acceptance for its virtual primary care services, including weight management for medically qualified patients. Initially available in select states, the company plans to continue enrollments with private payors to facilitate access to medically necessary services, ultimately having broad coverage options across all 50 states. As part of its early 2025 roadmap, LifeMD expects to begin accepting Medicare.
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00
KeyBanc Capital Markets initiated coverage of LifeMD with a rating of Overweight and set a new price target of $12.00
Craig Hallum initiated coverage of LifeMD with a rating of Buy and set a new price target of $10.00
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
10-Q - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
424B3 - LifeMD, Inc. (0000948320) (Filer)
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-717-1738International Dial-In:646-307-1865Conference ID:73461Live & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmac
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec